Abogen Biosciences
RU-friendlyChinese clinical-stage mRNA biotech — full in-house mRNA pipeline from protein engineering to commercial manufacturing; developed China's first domestic mRNA COVID vaccine.
- Country
- China
- Revenue
- ~$4M
- Employees
- ~53 emp
NMPA GMP
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| mRNA platforms & LNP delivery | therapeutics-platforms | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.